Emanate

The Phase 3 EMANATE trial is for individuals with rare forms of obesity caused by genetic variants

A randomized, double-blind, placebo-controlled trial to evaluate setmelanotide in multiple independent sub-studies. 

Participants in each sub-study include people 6 to 65 years old with  early-onset obesity and hyperphagia who carry certain genetic variants:

  • A variant in POMC or PCSK1 genes
  • A variant in the LEPR gene
  • A variant in the NCOA1 gene
  • A variant in the SH2B1 gene

Our exploratory Phase 2 Basket Trial established proof-of-concept in each of these genes. For more information, see data presentations from The Obesity Society’s ObesityWeek® 2021 and Obesity Medicine Association’s Overcoming Obesity 2021 Conference.

For more information, visit ClinicalTrials.gov.